title: Distinct cross-resistance profiles of the new protease inhibitors amprenavir, lopinavir, and atazanavir in a panel of clinical samples.
abstract: A panel of 245 clinical samples with known treatment histories was retrospectively evaluated for cross-resistance to new protease inhibitors (PI). Samples with resistance to previously approved PI displayed high cross-resistance to atazanavir, whereas cross-resistance to amprenavir was considerably lower. A similar cross-resistance profile was observed for lopinavir, if a higher cut-off for resistance (9.5-fold) was applied. The enhanced efficacy of boosted PI is discussed with respect to clinically relevant cut-offs for drug resistance.
authors.affiliation: Institute of Clinicaland Molecular Virology, German National Reference Centre for Retroviruses, University of Erlangen-Nuremburg, Erlangen, Germany.
authors.forename: Tanja
authors.initials: T
authors.lastname: Schnell
authors.forename: Barbara
authors.initials: B
authors.lastname: Schmidt
authors.forename: Gitta
authors.initials: G
authors.lastname: Moschik
authors.forename: Christine
authors.initials: C
authors.lastname: Thein
authors.forename: Christiane
authors.initials: C
authors.lastname: Paatz
authors.forename: Klaus
authors.initials: K
authors.lastname: Korn
authors.forename: Hauke
authors.initials: H
authors.lastname: Walter
mesh_terms: D000069446:Atazanavir Sulfate; D002219:Carbamates; D024921:Drug Resistance, Multiple, Viral; D005663:Furans; D006678:HIV / Q000187:drug effects*; D017320:HIV Protease Inhibitors / Q000494:pharmacology*; D006801:Humans; D061466:Lopinavir; D009842:Oligopeptides / Q000494:pharmacology; D011725:Pyridines / Q000494:pharmacology; D011744:Pyrimidinones / Q000494:pharmacology; D012189:Retrospective Studies; D013449:Sulfonamides / Q000494:pharmacology
chemical_list: D002219:Carbamates; D005663:Furans; D017320:HIV Protease Inhibitors; D009842:Oligopeptides; D011725:Pyridines; D011744:Pyrimidinones; D013449:Sulfonamides; D061466:Lopinavir; D000069446:Atazanavir Sulfate; C095108:amprenavir